tasquinimod
Phase 2- Indications
- Multiple myeloma, Myelofibrosis
Company intelligence / Profile preview
Active Biotech Ipsen
Lund, Swedenactivebiotech.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
Tasquinimod: Currently in phase Ib/IIa for hematological cancers; past Phase III program for prostate cancer (co-developed with Ipsen, which ended after negative results). Laquinimod: Eye drop formulation in clinical studies for inflammatory eye disease, previously developed for MS (licensed to Teva; development discontinued in CNS). Naptumomab estafenatox: Ongoing phase Ib/II for solid tumors via NeoTX partnership.
- Therapeutic areas
- HematologyNeurologyOncologyOphthalmology
- Modalities
- Small moleculeAntibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Ipsen (partnered on tasquinimod for prostate cancer)Teva (laquinimod CNS license, now inactive)NeoTX Therapeutics (naptumomab estafenatox license)
Beyond the preview
Go deeper on Active Biotech Ipsen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Active Biotech Ipsen.